Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients

World Journal of Hepatology

Volumn 4, Issue 12, 2012, Pages 382-388

  Vargas, Víctor ^a,b   Allende, Helena ^a,b   Lecube, Albert ^a,c   Salcedo, Maria Teresa ^a   Baena Fustegueras, Juan A ^d   Fort, José M ^d   Rivero, Joaquín ^e   Ferrer, Roser ^a   Catalán, Roberto ^a   Pardina, Eva ^f   Cajal, Santiago Ramón ^a   Guardia, Jaime ^a,b   Peinado Onsurbe, Julia ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e Barcelona University ^*  (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bariatric surgery; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity

Indexed keywords

EID: 84888049774     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i12.382     Document Type: Article

References (36)

1. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349-362
2. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100
3. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229
4. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107
5. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-419
6. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413
7. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, Bass DD. Fatty liver--an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92: 73-79
8. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419
9. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106
10. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654
11. Jaskiewicz K, Raczynska S, Rzepko R, Sledzinski Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006; 51: 21-26
12. Stratopoulos C, Papakonstantinou A, Terzis I, Spiliadi C, Dimitriades G, Komesidou V, Kitsanta P, Argyrakos T, Hadjiyannakis E. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15: 1154-1160
13. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226
14. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Rouxen- Y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368-373
15. Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin Liver Dis 2004; 24: 371-379
16. Fobi MA. Vertical Banded Gastroplasty vs Gastric Bypass: 10 years follow-up. Obes Surg 1993; 3: 161-164
17. Capella JF, Capella RF. The weight reduction operation of choice: vertical banded gastroplasty or gastric bypass. Am J Surg 1996; 171: 74-79
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30 Suppl 1: S42-S47
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359
21. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp- Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
23. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219
24. Hocking MP, Duerson MC, O'Leary JP, Woodward ER. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N Engl J Med 1983; 308: 995-999
25. Jewell WR, Hermreck AS, Hardin CA. Complications of jejunoileal bypass for morbid obesity. Arch Surg 1975; 110: 1039-1042
26. Kirkpatrick JR. Jejunoileal bypass. A legacy of late complications. Arch Surg 1987; 122: 610-614
27. Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 2004; 8: 535-547, viii
28. Requarth JA, Burchard KW, Colacchio TA, Stukel TA, Mott LA, Greenberg ER, Weismann RE. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch Surg 1995; 130: 318-325
29. Howard L, Malone M, Michalek A, Carter J, Alger S. Gastric Bypass and Vertical Banded Gastroplasty- a Prospective Randomized Comparison and 5-Year Follow-up. Obes Surg 1995; 5: 55-60
30. Capella JF, Capella RF. An assessment of vertical banded gastroplasty-Roux-en-Y gastric bypass for the treatment of morbid obesity. Am J Surg 2002; 183: 117-123
31. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610-617; discussion 618-620
32. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S, Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 48-58
33. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-1017
34. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, Louvet A, Dharancy S, Cocq P, Jany T, Boitard J, Deltenre P, Romon M, Pattou F. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006; 130: 1617-1624
35. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party. Hepatology 1998; 27: 1463-1466
36. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007; 11: 173-189